Entera Bio Stock Price

-0.21 (-3.95%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Entera Bio Ltd ENTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.21 -3.95% 5.10 18:21:46
Open Price Low Price High Price Close Price Prev Close
5.29 5.11 5.40 5.19 5.31
Bid Price Ask Price Spread News
5.10 5.20 0.10 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
775 85,639 $ 5.24 $ 448,761 - 1.00 - 10.16
Last Trade Time Type Quantity Stock Price Currency
19:23:45 1 $ 5.20 USD


Draw Mode:

Entera Bio Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 92.99M 18.23M 6.31M $ 365.00k $ - -1.08 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

Entera Bio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ENTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.935.544.935.34304,6110.173.45%
1 Month5.98356.604.915.83745,661-0.8835-14.77%
3 Months3.378.682.826.253,449,6681.7351.34%
6 Months1.671110.161.225.396,701,8193.43205.19%
1 Year1.9410.161.005.193,537,9903.16162.89%
3 Years5.9010.161.005.061,286,786-0.80-13.56%
5 Years7.3010.161.005.061,256,400-2.20-30.14%

Entera Bio Description

Entera Bio Ltd is a clinical-stage biopharmaceutical company which focuses on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. The lead oral parathyroid hormone (PTH) product candidate, EB612 for the treatment of hypoparathyroidism. The company also develops a varied oral PTH product candidate, EB613 for the treatment of osteoporosis.
Your Recent History
Entera Bio
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210727 00:22:25